Efficacy of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Chronic Lymphocytic Leukemia: A Serologic and Cellular Study

This study was undertaken to assess humoral immune and cellular responses to the BNT162b2 messenger RNA (mRNA) COVID-19 vaccination in CLL. Methods: The presence of the spike antibodies was assessed at a median time of 14 days from the second vaccine dose of SARS-CoV2 in 70 CLL followed-up at a single institution. Results: The antibody response rate (RR) in CLL patients was 58.5%, compared to 100% of 57 healthy controls of the same sex and age (P
Source: Chemotherapy - Category: Cancer & Oncology Source Type: research

Related Links:

New Brunswick, N.J. (January 25, 2022) – Johnson &Johnson (NYSE: JNJ) today announced results for fourth-quarter and full year 2021. “Our 2021 performance reflects continued strength across all segments of our business. Guided by Our Credo, I am honored to assume the role of CEO, leading our global teams in continuing our work to deliver life-changing solutions to consumers, patients, and health care providers” said Joaquin Duato, Chief Executive Officer. “Given our strong results, financial profile, and innovative pipeline we are well positioned for success in 2022 and beyond.” OVERALL FI...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Financial Source Type: news
Blood Adv. 2022 Jan 24:bloodadvances.2021006627. doi: 10.1182/bloodadvances.2021006627. Online ahead of print.ABSTRACTChronic lymphocytic leukemia (CLL), the most common leukemia worldwide, is associated with increased COVID-19 mortality. Previous studies suggest only a proportion of vaccinated CLL patients develop SARS-CoV-2 spike antibodies. Whether the elicited antibodies are functional and/or accompanied by functional T-cell responses is unknown. This prospective cohort study (NCT05007860) included patients with CLL who received SARS-CoV-2 and PCV13 vaccines (not concurrently). The primary cohort included adults with C...
Source: Adv Data - Category: Epidemiology Authors: Source Type: research
Conclusions. SARS-CoV-2 infection in CLL patients is associated with poor outcome regardless of administered CLL-directed treatment.
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
AbstractPurpose of ReviewChronic lymphocytic leukemia (CLL) is the most frequent lymphoproliferative disease in the elderly of the western world. Immune defective responses and treatment can worsen the immune system ’s competence of CLL patients. Consequently, they may present a higher incidence of recurrent severe infections, second malignancies, and reduced efficacy of vaccines. The outbreak of COVID-19 is an ongoing pandemic, and patients with comorbidities experience more severe forms of the disease. Hema tological malignancies are associated with higher case fatality rates (CFRs) than other cancers. Knowledge ab...
Source: Current Oncology Reports - Category: Cancer & Oncology Source Type: research
Chest. 2022 Jan;161(1):e5-e11. doi: 10.1016/j.chest.2021.08.045.ABSTRACTA 67-year-old obese man (BMI 38.0) with type 2 diabetes mellitus (DM), chronic atrial fibrillation, and chronic lymphocytic leukemia stage II, stable for 8 years after chemotherapy, and a history of smoking presented to the ED with progressive dyspnea and fever due to SARS-CoV-2 infection. He was admitted to a general ward and treated with dexamethasone (6 mg IV once daily) and oxygen. On day 3 of hospital admission, he became progressively hypoxemic and was admitted to the ICU for invasive mechanical ventilation. Dexamethasone treatment was continued,...
Source: Chest - Category: Respiratory Medicine Authors: Source Type: research
There is an urgent need for highly efficacious antiviral therapies in immunosuppressed hosts who develop coronavirus disease (COVID-19), with special concern for those affected by hematological malignancies.
Source: Journal of Hematology and Oncology - Category: Hematology Authors: Tags: Letter to the Editor Source Type: research
Leukemia, Published online: 22 December 2021; doi:10.1038/s41375-021-01500-1SARS-CoV-2 specific cellular response following COVID-19 vaccination in patients with chronic lymphocytic leukemia
Source: Leukemia - Category: Hematology Authors: Source Type: research
Haematologica. 2021 Dec 16. doi: 10.3324/haematol.2021.280163. Online ahead of print.ABSTRACTVaccines against SARS-CoV-2 have shown remarkable efficacy and thus constitute an important preventive option against COVID-19, especially in fragile patients. We aimed to systematically analyse the outcomes of patients with haematological malignancies who received vaccination and to identify specific groups with differences in outcomes. The primary end point was antibody response after full vaccination (two doses of mRNA or one dose of vector-based vaccines). We identified 49 studies comprising 11086 individuals. Overall risk of b...
Source: Haematologica - Category: Hematology Authors: Source Type: research
ConclusionThese findings show that haplotype diversity of SARS-CoV-2 may result in viral adaptation for persistent shedding in multiple recurrences of COVID-19 patients, who met the discharge requirement. However, the correlation between haplotype diversity of SARS-CoV-2 virus and immune status is not absolute. It showed important implications for the clinical management strategies for COVID-19 patients with long-term hospitalization or cases of recurrence.
Source: Frontiers in cellular and infection microbiology - Category: Microbiology Source Type: research
In conclusion, patients with CLL/lymphomas have low humoral response following COVID-19 vaccination, underlining the need for timely vaccination ideally during a treatment-free period and for continuous vigilance on infection control measures.
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
More News: Cancer & Oncology | Chemotherapy | Chronic Leukemia | Chronic Lymphocytic Leukemia | COVID-19 | Leukemia | SARS | Study | Vaccines